The economic burden of dry eye disease in the United States: a decision tree analysis
- PMID: 21045640
- DOI: 10.1097/ICO.0b013e3181f7f363
The economic burden of dry eye disease in the United States: a decision tree analysis
Abstract
Purpose: The aim of this study was to estimate both the direct and indirect annual cost of managing dry eye disease (DED) in the United States from a societal and a payer's perspective.
Methods: A decision analytic model was developed to estimate the annual cost for managing a cohort of patients with dry eye with differing severity of symptoms and treatment. The direct costs included ocular lubricants, cyclosporine, punctal plugs, physician visits, and nutritional supplements. The indirect costs were measured as the productivity loss because of absenteeism and presenteeism. The model was populated with data that were obtained from surveys that were completed by dry eye sufferers who were recruited from online databases. Sensitivity analyses were employed to evaluate the impact of changes in parameters on the estimation of costs. All costs were converted to 2008 US dollars.
Results: Survey data were collected from 2171 respondents with DED. Our analysis indicated that the average annual cost of managing a patient with dry eye at $783 (variation, $757-$809) from the payers' perspective. When adjusted to the prevalence of DED nationwide, the overall burden of DED for the US healthcare system would be $3.84 billion. From a societal perspective, the average cost of managing DED was estimated to be $11,302 per patient and $55.4 billion to the US society overall.
Conclusions: DED poses a substantial economic burden on the payer and on the society. These findings may provide valuable information for health plans or employers regarding budget estimation.
Similar articles
-
Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.Arch Pediatr Adolesc Med. 2005 Dec;159(12):1136-44. doi: 10.1001/archpedi.159.12.1136. Arch Pediatr Adolesc Med. 2005. PMID: 16330737
-
United States cost-effectiveness study of two dry eye ophthalmic lubricants.Ophthalmic Epidemiol. 2009 Jan-Feb;16(1):22-30. doi: 10.1080/09286580802521309. Ophthalmic Epidemiol. 2009. PMID: 19191178
-
Prevalence, burden, and pharmacoeconomics of dry eye disease.Am J Manag Care. 2008 Apr;14(3 Suppl):S102-6. Am J Manag Care. 2008. PMID: 18452369 Review.
-
Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients.Arch Dermatol. 2008 Jan;144(1):35-9. doi: 10.1001/archdermatol.2007.5. Arch Dermatol. 2008. PMID: 18209166
-
What We Know About the Epidemiology of Dry Eye Disease in Japan.Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES1-DES6. doi: 10.1167/iovs.17-23491. Invest Ophthalmol Vis Sci. 2018. PMID: 30481799
Cited by
-
The Properties and Role of O-Acyl-ω-hydroxy Fatty Acids and Type I-St and Type II Diesters in the Tear Film Lipid Layer Revealed by a Combined Chemistry and Biophysics Approach.J Org Chem. 2021 Apr 2;86(7):4965-4976. doi: 10.1021/acs.joc.0c02882. Epub 2021 Mar 17. J Org Chem. 2021. PMID: 33729799 Free PMC article.
-
The relationship between sex hormone levels and ocular surface parameters in girls with idiopathic central precocious puberty.Front Endocrinol (Lausanne). 2024 Jul 25;15:1429154. doi: 10.3389/fendo.2024.1429154. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39119007 Free PMC article.
-
Evaluation of the Regenerative Potential of Platelet-Lysate and Platelet-Poor Plasma Derived from the Cord Blood Units in Corneal Wound Healing Applications: An In Vitro Comparative Study on Corneal Epithelial Cells.Curr Issues Mol Biol. 2022 Sep 22;44(10):4415-4438. doi: 10.3390/cimb44100303. Curr Issues Mol Biol. 2022. PMID: 36286018 Free PMC article.
-
Prevalence of dry eye and Meibomian gland dysfunction in Central and South America: a systematic review and meta-analysis.BMC Ophthalmol. 2024 Jan 31;24(1):50. doi: 10.1186/s12886-023-03249-w. BMC Ophthalmol. 2024. PMID: 38297204 Free PMC article.
-
A Novel Integrated Active Herbal Formulation Ameliorates Dry Eye Syndrome by Inhibiting Inflammation and Oxidative Stress and Enhancing Glycosylated Phosphoproteins in Rats.Pharmaceuticals (Basel). 2020 Oct 7;13(10):295. doi: 10.3390/ph13100295. Pharmaceuticals (Basel). 2020. PMID: 33036453 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical